GLP-1RA和减少牛皮的死亡率,心血管和精神疾病风险:一项大型队列研究
Henning Olbrich1, Khalaf Kridin2,3,4, Henner Zirpel5
1Department of Dermatology, Allergy, and Venerology, University of Lübeck, Lübeck, Germany.
The British journal of dermatology
|September 2, 2025
概括
在肥胖或糖尿病的牛皮患者中,葡萄糖类-1受体激动剂 (GLP- 1RA) 显著降低了死亡率和心血管风险. 这种安全的治疗也降低了精神疾病的风险,而牛皮患者的益处更大.
科学领域:
- 皮肤病学
- 心脏病学
- 内分泌学
背景情况:
- 牛皮与严重的心血管和代谢问题有关.
- 葡萄糖类-1受体激活剂 (GLP-1RA) 用于肥胖和糖尿病,可能有利于牛皮患者.
研究的目的:
- 评估GLP- 1RA对牛皮患者的死亡率,心血管,炎症和精神结果的影响.
- 在该群体中评估与GLP- 1RA相关的不良事件.
主要方法:
- 使用美国 TriNetX 数据进行的基于人口的回顾性队列研究.
- 在倾向性得分匹配后,对GLP- 1RA治疗的3048名牛皮患者进行了比较.
- 分析心脏代谢,精神病,自身免疫结果,死亡率和不良事件;在非牛皮群中得到验证.
主要成果:
- 在牛皮患者中,GLP- 1RA使用与显著降低全因死亡率 (HR 0. 219) 和主要心脏不良事件 (MACE) (HR 0. 561) 相关.
- 观察到酒精和药物滥用的风险降低.
- 典型的药物不良事件没有增加;风险降低大于非牛皮群.
结论:
- 对于肥胖或糖尿病的牛皮患者,GLP- 1RA治疗是安全的.
- 在这一群体中,GLP- 1RA显著降低了心血管和精神疾病相关的风险和死亡率.
- 医生应考虑使用GLP- 1RA治疗伴随肥胖或糖尿病的牛皮患者.
相关概念视频
Glucagon-like Receptor Agonists
416
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
416
Dipeptidyl Peptidase 4 Inhibitors
252
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
252
Psychoneuroimmunology: Cardiovascular Disease
77
Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
A key area of focus in PNI is the relationship between stress and coronary...
77
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
251
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
251
Oral Hypoglycemic Agents: Biguanides and Glitazones
288
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
288
GPCRs Regulate Adenylyl Cylase Activity
5.9K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.9K


